🇺🇸 RCUS — Arcus Biosciences, Inc.

Salud Compra fuerte
← Volver

Precio actual

19,31 USD

Máx. histórico

48,47

1807 días

Caída desde máximo

-60,16%

Rango 52 semanas

17,43 – 31,74

Variación hoy

+2,12%

Cierre anterior

18,91

Rango de hoy

18,60 – 19,61

Volumen hoy

2.076.185

Peor caída histórica

-85,83%

23/11/2021 → 04/04/2025

Aún sin recuperar

Volatilidad anualizada ⓘ

75,61%

Información
Nombre completo
Arcus Biosciences, Inc.
Divisa
USD
Mercado
NYSE
Sector
Salud
Industria
Biotechnology
Empleados
601
PER ⓘ
—
Dividend yield
0,00% (puede no estar actualizado)
Precio objetivo analistas
41,00 USD (puede no estar actualizado)
Primera cotización
15/03/2018
Precio actualizado
hace 13 horas
Sobre la empresa

Arcus Biosciences, Inc., a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States. The company's development product portfolio includes Casdatifan, a HIF-2a inhibitor for the treatment of kidney cancer; Domvanalimab, an anti-TIGIT antibody, which is in Phase 2 and Phase 3 clinical trial for lung and gastrointestinal cancers; and Zimberelimab, an anti-PD-1 antibody. It also develops Quemliclustat, a small molecule inhibitor that targets the CD73 enzyme in the ATP-adenosine pathway, which is in phase 3 and phase 1/1b clinical trial for lung and pancreatic cancer. In addition, the company develops AB598, a CD39 antibody, which is in phase 1/1b clinical study for gastrointestinal cancer and AB801, an AXL inhibitor, which is in Phase 1b clinical trial for lung cancer. It has clinical collaboration with AstraZeneca for the Phase 3 PACIFIC-8 trial evaluating domvanalimab and durvalumab in Stage 3 NSCLC and for a Phase 1/1b study evaluating casdatifan and volrustomig in IO-naive patients with ccRCC; BVF Partners L.P. to support the discovery and development of compounds for the treatment of inflammatory diseases; and Bristol-Myers Squibb Company to develop a novel treatment regimen that delivers tumor control in kidney cancer. Arcus Biosciences, Inc. was incorporated in 2015 and is based in Hayward, California.

Rentabilidad mensual
Evolución
Histórico día a día
Fecha Apertura Máximo Mínimo Cierre Variación Volatilidad día Volumen
26/05/2020 36,38 36,61 33,33 33,54 -6,26% 9,02% 314.300
22/05/2020 36,35 36,63 34,78 35,78 -1,54% 5,08% 246.600
21/05/2020 36,66 37,41 35,78 36,34 -0,60% 4,45% 386.400
20/05/2020 34,12 36,71 33,62 36,56 +8,78% 9,06% 503.900
19/05/2020 33,53 34,38 33,23 33,61 -0,97% 3,43% 330.700
18/05/2020 35,76 36,79 33,14 33,94 -3,11% 10,22% 660.700
15/05/2020 31,35 36,19 30,89 35,03 +10,19% 16,91% 1.292.600
14/05/2020 28,21 32,37 26,85 31,79 +2,48% 19,59% 1.691.400
13/05/2020 29,22 32,69 28,64 31,02 +5,91% 13,87% 873.300
12/05/2020 30,49 30,84 29,15 29,29 -3,81% 5,54% 971.900
11/05/2020 29,87 30,96 29,17 30,45 +1,23% 5,98% 705.900
08/05/2020 29,65 30,81 27,94 30,08 +1,18% 9,68% 827.100
07/05/2020 27,93 31,00 26,80 29,73 +10,89% 15,04% 841.500
06/05/2020 27,00 27,39 25,90 26,81 -1,22% 5,52% 353.100
05/05/2020 27,29 27,63 26,53 27,14 +0,52% 4,03% 1.286.200
04/05/2020 25,76 27,17 25,31 27,00 +2,97% 7,22% 653.900
01/05/2020 26,08 27,27 25,80 26,22 -0,72% 5,64% 381.700
30/04/2020 28,11 28,31 25,71 26,41 -5,98% 9,25% 608.800
29/04/2020 27,26 28,89 26,89 28,09 +4,50% 7,35% 733.900
28/04/2020 28,79 28,79 26,70 26,88 -4,55% 7,26% 478.400
27/04/2020 29,03 29,25 27,84 28,16 -2,90% 4,86% 410.400
24/04/2020 28,54 29,19 28,53 29,00 +0,24% 2,31% 577.400
23/04/2020 29,23 29,99 28,02 28,93 -1,67% 6,74% 624.000
22/04/2020 29,61 30,32 29,02 29,42 -0,64% 4,37% 514.600
21/04/2020 29,78 30,58 28,15 29,61 -1,56% 8,15% 666.600
20/04/2020 27,19 30,86 26,11 30,08 +7,01% 17,47% 980.700
17/04/2020 32,00 36,33 27,37 28,11 -4,71% 28,00% 2.619.100
16/04/2020 17,14 31,00 17,14 29,50 +89,35% 80,86% 4.975.400
15/04/2020 16,47 16,67 15,32 15,58 -7,21% 8,20% 594.400
14/04/2020 17,01 17,48 16,43 16,79 +0,12% 6,14% 297.700